Sarcoidosis of the nervous system.
Although sarcoidosis is rarely confined to the nervous system, any neurological features that do occur frequently happen early in the course of the disease. The most common neurological presentation is with cranial neuropathies, but seizures, chronic meningitis and the effects of mass lesions are also frequent. The diagnostic process should first confirm nervous system involvement and then provide supportive evidence for the underlying disease; in the absence of any positive tissue biopsy, the most useful diagnostic tests are gadolinium enhanced MRI of the brain and CSF analysis, although both are non-specific. The mainstay of treatment is corticosteroids, but these often have to be combined with other immunosuppressants such as methotrexate, hydroxychloroquine or cyclophosphamide. There is increasing evidence that infliximab is a safe treatment with good steroid sparing capacity.
Joseph
F G
FG
Department of Neurology, Institute of Clinical Neurosciences, University of Bristol, Bristol, UK.
Scolding
N J
NJ
D020274:Autoimmune Diseases of the Nervous System / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D001921:Brain / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D003389:Cranial Nerve Diseases / Q000276:immunology / Q000503:physiopathology*; D006099:Granuloma / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008582:Meningitis, Aseptic / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D009901:Optic Nerve Diseases / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D012507:Sarcoidosis / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D019291:Skull Base / Q000473:pathology / Q000503:physiopathology
D007166:Immunosuppressive Agents